Jewish General Hospital
jgh.caTotal trials
95
Active
15
Phase 3
4
Total enrollment
257,530
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Maltodextrin solution | — | — | — | — | — | 1 | |
| Fecal Microbiota Transplantation | — | — | — | — | — | 1 | |
| Ipilimumab | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | — | — | 1 |
Next readouts
- 2017-02
- 2026-12-01
- 2029-12
Top conditions
- Quality of Life6
- Frailty6
- Rectal Cancer5
- Low Anterior Resection Syndrome4
- Old Age4
- Emergencies4
- Social Interaction3
- Neurocognitive Disorders3
Frequently asked questions about Jewish General Hospital
- How many clinical trials does Jewish General Hospital have on ClinicalTrials.gov?
- Jewish General Hospital is listed as the lead sponsor on 95 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Jewish General Hospital's trials are in Phase 3?
- 4 of Jewish General Hospital's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Jewish General Hospital focus on?
- Jewish General Hospital's most-studied conditions on ClinicalTrials.gov are Quality of Life, Frailty, Rectal Cancer, Low Anterior Resection Syndrome, Old Age.
- When are Jewish General Hospital's next clinical trial readouts?
- Jewish General Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma”, expected around 2017-02.